BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union

Rhea-AI Summary

BD (NYSE:BDX) announced CE Marking for the Liverty™ TIPS Stent Graft, an adjustable‑diameter device (6–10 mm) designed to treat portal hypertension complications across the EU. Safety and effectiveness data from the pivotal ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Meeting on April 12, 2026.

The device offers a broad range of covered TIPS stent lengths, a flexible nitinol frame, dual‑layer ePTFE encapsulation, and a triaxial delivery system. In the U.S. the device remains investigational.

Positive

• CE Mark granted for Liverty TIPS Stent Graft enabling EU market access
• Adjustable inner diameter range of 6–10 mm for individualized therapy
• Broadest range of covered TIPS stent lengths currently available
• Pivotal ARCH trial safety and effectiveness data slated for April 12, 2026 presentation

Negative

• Device remains investigational and not approved for clinical use in the United States
• ARCH trial is a single‑arm study, limiting direct comparative evidence

News Market Reaction – BDX

+1.37%

+1.37% Session close to close

In the Apr 8 session, BDX gained 1.37%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights BD’s push into advanced liver disease care with the Liverty™ TIPS Stent...

Analysis

This announcement highlights BD’s push into advanced liver disease care with the Liverty™ TIPS Stent Graft, supported by CE Marking and forthcoming ARCH trial data at SIR on April 12, 2026. The device’s 6–10 mm adjustable diameter and nitinol/ePTFE construction aim to personalize portal hypertension treatment. Against a backdrop of recent monitoring, AI dispensing, and surgical innovations, investors may watch for detailed efficacy and safety outcomes and adoption signals in EU clinical practice.

Key Figures

Global cirrhosis prevalence: 58 million people Adjustable inner diameter: 6–10 mm ARCH study design: Single-arm, multi-center +1 more

4 metrics

Global cirrhosis prevalence 58 million people Estimated worldwide cirrhosis burden

Adjustable inner diameter 6–10 mm Liverty™ TIPS Stent Graft inner diameter range

ARCH study design Single-arm, multi-center Global prospective clinical study of Liverty™ TIPS Stent Graft

SIR presentation date April 12, 2026 First public presentation of ARCH clinical trial data

Historical Context

5 past events · Latest: Apr 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 07	Monitoring device launch	Positive	-0.2%	Launch of HemoSphere Stream™ Module for continuous noninvasive blood pressure monitoring.
Apr 01	AI med dispensing	Positive	-0.6%	European rollout of AI-enabled BD Pyxis Pro and BD Incada Connected Care Platform.
Mar 02	FDA 510(k) clearance	Positive	+0.0%	510(k) clearance for Surgiphor™ 1000mL antimicrobial wound irrigation system.
Feb 25	Tender pricing	Negative	-2.4%	Pricing and allocations for up to $2,000,000,000 of senior note tenders.
Feb 25	Tender upsizing	Negative	-0.8%	Upsizing Aggregate Offer Cap to $2,000,000,000 and higher sub-cap for 4.685% notes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent product and technology launches with seemingly positive implications have often coincided with flat-to-negative next-day returns, while liability management actions tied to large note tenders have seen more clearly negative reactions.

Recent Company History

Over the last few months, BD has focused on innovation and balance sheet actions. Product launches such as the HemoSphere Stream™ Module, the BD Pyxis Pro Dispensing Solution, and FDA-cleared Surgiphor™ 1000mL highlighted expansions in monitoring, medication management and surgical safety. In parallel, BD executed sizable debt tender offers capped at $2,000,000,000. Those tenders drew the largest negative price reactions, while product-related releases produced flat to modestly negative moves. Today’s EU-focused TIPS stent graft news fits the pattern of clinical and procedural innovation updates.

Key Terms

ce marking, portal hypertension, cirrhosis, transjugular intrahepatic portosystemic shunt (tips), +3 more

7 terms

ce marking regulatory

"today announced application of CE Mark for the Liverty™ TIPS Stent Graft"

CE marking is a symbol placed on certain products showing they meet European Union safety, health and environmental rules required to sell them in the EU/EEA. For investors, it signals that a product has cleared a common regulatory hurdle—like a passport for market access—reducing legal and market-entry risk and often widening sales opportunities across European markets.

portal hypertension medical

"portal hypertension, a serious condition that can result in life‑threatening complications"

An increase in blood pressure in the portal venous system — the veins that carry blood from the intestines to the liver — usually caused by scarring or blockage in the liver that acts like a traffic jam in a pipe. It matters to investors because it drives demand for treatments, diagnostics and procedures, influences clinical trial outcomes and regulatory decisions, and can materially affect healthcare costs and a company’s commercial prospects in liver-related therapies.

cirrhosis medical

"Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension"

Cirrhosis is long-term damage to the liver in which healthy tissue is replaced by scar tissue, leaving the organ stiff and less able to do jobs like filtering blood, making proteins and processing nutrients—think of a sponge that has been hardened and can no longer soak or squeeze properly. Investors care because cirrhosis drives demand for medicines, medical devices and hospital care, affects clinical trial populations and regulatory risk, and can influence healthcare costs, insurance liabilities and workforce productivity.

transjugular intrahepatic portosystemic shunt (tips) medical

"Transjugular intrahepatic portosystemic shunt (TIPS) procedures help reduce symptoms"

A transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive procedure that creates a new channel inside the liver between two blood vessels by threading a tube in from a neck vein and placing a small metal stent, relieving dangerously high blood pressure in the liver’s circulation. Think of it as building a bypass road around a traffic jam; for investors, TIPS matters because changes in procedure use, device sales, hospital revenues, safety outcomes, or reimbursement rules can directly affect makers of stents and related equipment, hospitals, and companies developing complementary therapies.

stent graft medical

"The Liverty™ TIPS Stent Graft is engineered to support individualized patient management"

A stent graft is a tube-shaped medical device made of a metal scaffold covered with fabric that is placed inside a blood vessel to reinforce weakened walls and seal leaks, much like inserting a strong inner sleeve to patch a worn pipe. Investors monitor stent grafts because their regulatory approvals, clinical success, manufacturing capacity and reimbursement determine sales potential and legal or safety risks that can significantly affect a medical device maker’s revenue and valuation.

nitinol technical

"flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation"

Nitinol is a nickel‑titanium metal alloy known for “shape memory” and spring‑like flexibility: it can return to a preset shape after bending or heating, like a paperclip that snaps back when warmed. Investors track it because those unique properties make it a go‑to material for medical implants, surgical tools and precision devices, so changes in availability, cost, regulation or technical advances can directly affect manufacturers’ product performance, margins and regulatory risk.

eptfe technical

"dual-layer ePTFE encapsulation with carbon impregnation on the inner surface"

Expanded polytetrafluoroethylene (ePTFE) is a lightweight, very slippery, and porous plastic material made by stretching a Teflon-like polymer into a fine, fibrous structure—think of it as a breathable, nonstick fabric with microscopic holes. It matters to investors because ePTFE is used in medical implants, surgical grafts, filters and high-performance industrial parts; its unique properties affect product performance, regulatory approval, manufacturing complexity and pricing, all of which can shape a company’s sales, costs and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease

FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty™ TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, our next‑generation, adjustable‑diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease. Safety and effectiveness data from the pivotal ARCH clinical trial evaluating the Liverty™ TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on April 12, 2026.

Cirrhosis remains a significant global health challenge, with an estimated 58 million people worldwide living with the disease, according to the latest findings from the Global Burden of Disease study.¹ Cirrhosis can lead to portal hypertension, a serious condition that can result in life‑threatening complications such as variceal bleeding and fluid build-up in the abdomen or chest. ² Transjugular intrahepatic portosystemic shunt (TIPS) procedures help reduce symptoms caused by elevated portal pressure by lowering that pressure and improving blood flow.

The Liverty™ TIPS Stent Graft is engineered to support individualized patient management, offering a 6–10 mm adjustable inner diameter and the broadest range of covered TIPS stent lengths currently available. Key features include a flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation with carbon impregnation on the inner surface, delivered fully constrained on a triaxial delivery system designed for placement accuracy, control and ease of use.

"For patients living with complications of portal hypertension, access to safe, effective and adaptable treatment options is critical," said Rima Alameddine, worldwide president of Peripheral Intervention at BD. "With CE Marking of the Liverty™ TIPS Stent Graft, we're introducing an innovative, adjustable solution that helps physicians personalize therapy and improve the potential for long‑term outcomes."

BD also announced that data from the ARCH clinical study, a global, prospective, multi‑center, single‑arm clinical study assessing the safety and effectiveness of the Liverty™ TIPS Stent Graft for the treatment of complications from portal hypertension, will be presented for the first time on podium by Global Principal Investigator Prof. Ziv Haskal, MD, at SIR in April.

"The Liverty™ TIPS Stent Graft represents an important advancement in how we care for patients with the serious complications of portal hypertension," said Dr. Haskal. "Its adjustable diameter and delivery design allow physicians to better match the shunt to a patient's unique physiology, a key consideration in safe and effective TIPS creation. The trial provides the first and only prospective data describing the results of small diameter calibrated TIPS for treating all the major complications of portal hypertension. I look forward to presenting the ARCH study results at SIR."

In the United States, the Liverty™ TIPS Stent Graft it is an investigational device limited by U.S. law to investigational use only.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

________________________________
¹ Duo H, You J, Du S, Yu M, Wu S, Yue P, et al. Liver cirrhosis in 2021: Global Burden of Disease study. PLOS One. 2025;20(7):e0328493. doi: 10.1371/journal.pone.032849
² Carroll A, Boike JR. Tips for TIPS recipients: A patient-focused guidance on TIPS. Clin Liver Dis (Hoboken). 2024;23(1):e0091. doi:10.1097/CLD.0000000000000091

Contacts:
Media	Investors
Matt Marcus VP, Public Relations Matt.Marcus@bd.com	Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-delivers-nextgeneration-tips-innovation-to-advance-portal-hypertension-care-across-the-european-union-302734817.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What does CE Marking of the Liverty TIPS Stent Graft mean for BDX shareholders?

CE Marking permits commercial distribution of the Liverty TIPS Stent Graft across the EU, expanding market opportunity. According to the company, CE Mark enables BD to offer the adjustable 6–10 mm device to European clinicians, potentially accelerating adoption for portal hypertension care.

When and where will ARCH clinical trial results for Liverty (BDX) be presented?

ARCH trial data will be presented on podium at the Society of Interventional Radiology meeting on April 12, 2026. According to the company, Global Principal Investigator Prof. Ziv Haskal will present safety and effectiveness results for the Liverty TIPS Stent Graft.

What are the key design features of the Liverty TIPS Stent Graft (BDX)?

The device offers a flexible self‑expanding nitinol frame and dual‑layer ePTFE encapsulation with carbon impregnation. According to the company, it is delivered fully constrained on a triaxial system and provides the broadest covered TIPS lengths and a 6–10 mm adjustable diameter.

How does the Liverty adjustable diameter affect patient treatment options with BDX device?

The 6–10 mm adjustable inner diameter allows physicians to better match shunt size to patient physiology for individualized care. According to the company, adjustable sizing aims to improve TIPS creation safety and tailor treatment for portal hypertension complications.

Is the Liverty TIPS Stent Graft approved for use in the United States?

No, the Liverty TIPS Stent Graft is investigational and limited to investigational use in the United States. According to the company, U.S. use remains subject to investigational device regulations and is not approved for commercial clinical use.